Showing results (1-10 of 42) with videos related to

Sort By:
Pageof 5
Lung Cancer (Amsterdam, Netherlands)|April 12, 2020
Immune checkpoint inhibitors in special populations. A focus on advanced lung cancer patientsCorina Escoin-Perez, Sara Blasco, Oscar Juan-Vidal
Cancers|September 28, 2023
Sex Differences in the Efficacy of Immune Checkpoint Inhibitors in Neoadjuvant Therapy of Non-Small Cell Lung Cancer: A Meta-AnalysisGuillermo Suay, Juan-Carlos Garcia-Cañaveras, Francisco Aparisi, et al.
Revista Espanola De Geriatria Y Gerontologia|January 24, 2012
[Detection of dysphagia in the institutionalised elderly]María Isabel Ferrero López, José Fermín García Gollarte, José Jorge Botella Trelis, et al.
Briefings in Bioinformatics|March 1, 2023
FAMetA: a mass isotopologue-based tool for the comprehensive analysis of fatty acid metabolismMaría I Alcoriza-Balaguer, Juan C García-Cañaveras, Marta Benet, et al.
Cancer Letters|November 3, 2024
Immune checkpoint inhibitors as first-line treatment for brain metastases in stage IV NSCLC patients without driver mutationsGuillermo Suay, Juan-Carlos Garcia-Cañaveras, Francisco Aparisi, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|February 21, 2023
Sex differences in the diagnosis, treatment and prognosis of cancer: the rationale for an individualised approachRuth Vera, Oscar Juan-Vidal, María José Safont-Aguilera, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|April 18, 2025
Oncological needs in transgender patientsFrancisco Ayala de la Peña, David Martínez-Ramos, Oscar Juan-Vidal, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 7, 2023
SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022)Rosario García-Campelo, Ivana Sullivan, Edurne Arriola, et al.
Clinical Lung Cancer|April 11, 2022
A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to ErlotinibD Ross Camidge, Teresa Moran, Ingel Demedts, et al.
Frontiers in Oncology|March 1, 2021
nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+)Daniel Morgensztern, Manuel Cobo Dols, Santiago Ponce Aix, et al.
Pageof 5